Wednesday, August 16, 2017 12:22:39 AM
Individual checkpoint inhibitor therapies, e.g., Yervoy, Keytruda, Opdivo, etc. individually cost nearly $150,000 per year per patient. These drugs serve as the foundation to most immuno oncology regimens. Combining checkpoint inhibitors to improve efficacy comes with toxicities and obviously higher costs.
If indeed a high proportion of pre-existing partially exhausted TIL correspond with equal efficacy when comparing a monotherapy (anti-pd1) to a combination therapy (anti-CTLA4 and anti-pd1), then it seems apparent that you can achieve desired efficacies with anti-pd1 monotherapies - and potentially save a lot of money - as long as those exhausted TIL phenotypes are elevated. If ONCS is capable of achieving such a goal - i.e. getting to the point where they can increase the exhausted TIL phenotypes - then they may considerably reduce costs by negating the need for combination checkpoint inhibitor therapies. They essentially create the right TME conditions for monotherapy anti-pd1 drugs, for example. Can ONCS electroporate their product for under $150K/per year/per person to demonstrate savings?
Then of course we have the possibility that ONCS may start developing their own gene-encoded checkpoint inhibitors that could be delivered (via electroporation) systemically (e.g. anti-pd1) and intramurally (e.g. anti-CTLA4). It's right there in their patent application claims - this could lead to a significant disruption in the checkpoint inhibitor market and lead to massive savings in health care if they actually do it.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM